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Background: Patients with X-linked agammaglobulinemia (XLA) develop immune-complex induced diseases such
as nephropathy only rarely, presumably because their immunoglobulin (Ig) G concentration is low. We encountered
a patient with XLA who developed tubulointerstitial nephritis during treatment with intravenous immunoglobulin
(IVIG).
Case presentation: A 20-year-old man was diagnosed with XLA 3 months after birth and subsequently received
periodic γ-globulin replacement therapy. Renal dysfunction developed at 19 years of age in association with high
urinary β2-microglobulin (MG) concentrations. A renal biopsy specimen showed dense CD3-positive lymphocytic
infiltration in the tubulointerstitium and tubular atrophy, while no IgG4-bearing cell infiltration was found. Fibrosclerosis
and crescent formation were evident in some glomeruli. Fluorescent antibody staining demonstrated deposition of IgG
and complement component C3 in tubular basement membranes. After pulse steroid therapy was initiated,
urinary β2-MG and serum creatinine concentrations improved.
Conclusion: Neither drug reactions nor collagen disease were likely causes of tubular interstitial disorder in this
patient. Although BK virus was ruled out, IgG in the γ-globulin preparation might have reacted with a pathogen
present in the patient to form low-molecular-weight immune complexes that were deposited in the tubular
basement membrane.
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In X-linked agammaglobulinemia (XLA), mutation involv-
ing the Bruton agammaglobulin tyrosine kinase (BTK) gene
induces a B-cell maturation disorder that causes congenital
immunodeficiency in which repeated bacterial infections
reflect antibody production failure [1,2]. Prognosis for
survival is relatively favorable owing to immunoglobulin
replacement therapy (intravenous immunoglobulin therapy,
or IVIG) [3].
We encountered a patient with BTK gene mutation
(p.Gln412X)-induced XLA who developed renal dysfunc-
tion associated with increased urinary β2-microglobulin
during IVIG therapy. Renal histology indicated a tubu-
lar interstitial disorder. Glomerular immune complex* Correspondence: tsukasa@med.kindai.ac.jp
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unless otherwise stated.deposition such as in membranous nephropathy [4]
and membranoproliferative glomerulonephritis [5] oc-
casionally has been reported in association with IVIG
therapy for XLA. To our knowledge, however, tubu-
lointerstitial nephritis (TIN) showing immune complex
deposition in the tubular basement membrane has not
previously been reported in XLA patients receiving
IVIG therapy.Case presentation
A 20-year-old man who was diagnosed with XLA 3 months
after birth was treated periodically with IVIG. Mild renal
dysfunction developed at 19 years. Serum creatinine (Cr)
and blood urea nitrogen (BUN) were 1.5 and 30 mg/dL
respectively, and urinary β2-microglobulin was elevated.
The patient was admitted to our department for further
evaluation and treatment.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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1.017, 1+ qualitative protein, and 0.14 g/day quantita-
tive protein. Microscopy showed 1 to 4 red blood cells
per high-power field (HPF). White blood cells were 1
to 4 per HPF. Urine β2-microglobulin was 32550 μg/
day (normal, below 250), and N-acetyl-β-D-glucosami-
nidase was 17.9 U/L (normal, 0.3 to 11.5). Creatinine
clearance was 39.2 mL/min/1.73 m2 (normal, 65 to
142). The findings suggested tubular interstitial dis-
order causing renal dysfunction. No uveitis was de-
tected. On hematologic examination, the red blood cell
count was 548 × 104 /μL; white blood cell count, 8400 /μL;
platelet count, 15.5 × 104/μL; and erythrocyte sedimenta-
tion rate, 4 mm/hour. In serum, Na was 142 mEq/L; K,
3.9 mEq/L; C-reactive protein, 2.8 mg/dL; BUN, 30 mg/dL;
Cr, 1.29 mg/dL; and cystatin C, 1.96 mg/L (normal,
0.56 to 0.87). In sum, inflammatory markers were
mildly elevated and moderate renal dysfunction was
present. The IgG concentration was 685 mg/dL (nor-
mal, 870 to 1700 mg/dL); and IgM, below 20 mg/dL
(normal, 33 to 190 mg/dL). Complement components
were normal. Serum IgG4 concentration was below 1%
of total serum IgG concentration. All autoantibodies
were absent (antinuclear, anti-DNA, rheumatoid arth-
ritis hemagglutination antibodies, anti-cyclic citrullinated
peptide, anti-SS-A/Ro, anti-SS-B/La, and myeloperoxidase-
ANCA). On investigation for pathogens, cytomegalovirus
pp65 antigen, anti-VCA IgM antibody, and γ-interferon
specific for tuberculosis were not detected. Adenovirus,
herpes simplex virus, and BK virus were not detected by
real-time polymerase chain reaction. Lymphocyte stimula-
tion tests (DLST) with D-mannitol, glycine, and polyethyl-
ene glycol (all components of the patient’s γ-globulin
preparation) were negative. No physical, laboratory, or
radiologic findings suggesting Castleman disease or malig-
nant lymphoma were demonstrated.
Examination of renal biopsy specimen showed marked
mononuclear cell infiltration in the interstitium (Figure 1a),
and loss of tubular epithelial cells, cloudy degener-
ation, and irregularity of the basement membrane in
some renal tubules. Some glomeruli showed cellular
crescent formation (Figure 1b) and fibrosclerotic le-
sions. Fluorescent antibody staining detected granular
depositions of IgG (Figure 1c) and complement component
C3 in the tubular basement membrane. By electron micros-
copy (Figure 1d), electron-dense deposits were observed in
the tubular basement membrane. Immune cells infiltrating
in the tubulointerstitium were predominantly CD3 antigen-
positive lymphocytes (T-cells; Figure 1e), but not IgG4-
bearing cells (Figure 1f).
Steroid therapy was administered including methylpred-
nisolone pulse therapy followed by prednisolone (PSL).
Urinary findings and renal function slowly improved, and
progress continued after gradual dose reduction. Althoughthe patient still is receiving IVIG therapy, urinary ab-
normalities and renal function deterioration have not
recurred.
Discussion
Immune-comples induced nephritis and complement-
associated renal impairment are infrequent in XLA
patients, most likely because of their very low IgG con-
centrations [6]. We encountered a young man who de-
veloped tubulointerstitial nephritis (TIN) during IVIG
for XLA. Glomerular immune complex deposition re-
lated to membranous nephropathy [4] and membrano-
proliferative glomerulonephritis [5] during the course
of XLA have been reported occasionally. Nephrotic
syndrome with TIN during IVIG therapy for secondary
hypogammaglobulinemia during childhood has been
described [7]. However, the reporting authors concluded
that TIN might have been caused by a local allergic reac-
tion, considering a predominance of eosinophils among
cells infiltrating the tubulointerstitum. To our knowledge,
however, TIN induced by immune complex deposition in
the renal tubules, such as that occurring in our patient, has
not been reported previously.
In XLA, viral infections follow a normal course except
for enterovirus infection, in which effective host defense
requires antibodies. XLA patients are vulnerable to this
infection, which may become persistent and progressive
[8]. In our patient, IgG and complement deposits were
demonstrated in the tubular basement membrane by
fluorescent antibody staining and electron microscopy,
suggesting several possible pathogenetic mechanisms.
Complement may have been activated locally after im-
mune complex formation by interactions between an
antigen present in the patient and the IgG contained in
the γ-globulin preparation, inducing a tubular intersti-
tial disorder. However, no specific infection could be
identified in our patient. Although tubulointerstitial
immune-complex nephritis is a very rare form of TIN,
such nephritis can be caused by treatments such as
nonsteroidal anti-inflammatory drugs [9], by auto-
immune diseases such as lupus erythematosus [10], or
IgG4-related diseases [11]. However, our patient re-
ceived no long-term drug treatment apart from IVIG,
and had no collagen disease or IgG4-related disease
according to repeated laboratory examinations.
Wegmuller et al. [12] reported that complement
activation may occur in both healthy individuals and
patients with congenital humoral immunodeficiency. A
few B cells persist in XLA patients, producing a small
amount of IgG in some patients [13]. The exogenous,
non-self IgG infused in IVIG might have induced
autoantibody production against exogenous IgG with
consequent nephropathy, but this mechanism cannot
be proven in our patient; because to prevent fatal
Figure 1 Renal histologic findings in the patient. Marked tubulointerstitial mononuclear cell infiltration was observed (a; Masson
trichrome stain, ×100). Crescent formation was noted in some glomeruli (b; periodic acid-Schiff stain, ×200). Fluorescent antibody staining
demonstrated granular deposition of IgG in the tubular basement membrane (c; ×200). Electron-dense deposits were present in the tubular
basement membrane (d; original magnification, ×6000). Immune cells infiltrating in tubulointerstitial tissue were mainly CD3-positive T-cells
(e), as opposed to IgG4-bearing cells (f; ×200).
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ing measurement of self-produced IgG impossible.
When type III allergy is involved in disease develop-
ment and the antigen concentration exceeds the anti-
body concentration, immune complexes will have low
molecular weight and may well be deposited outside
the tubular basement membrane [14]. Alternatively,
antigen concentrations may be excessive in XLA pa-
tients, with low-molecular-weight immune complexes
formed in the circulation possibly passing through the
glomeruli to enter the urinary space and then depos-
ited in the tubular basement membrane.Conclusions
In patients with congenital humoral immunodeficiency
patients, vigilance is needed to detect development of
renal dysfunction during IVIG therapy. Not only glom-
erular disease but also TIN may occur, as occurred in
our patient.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images.
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